The importance of impurity analysis in pharmaceutical products: An integrated approach

Accreditation and Quality Assurance

Volumn 11, Issue 1-2, 2006, Pages 69-74

  Rahman, Nafisur ^a   Azmi, Syed Najmul Hejaz ^a   Wu, Hui Fen ^b  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b TAMKANG UNIVERSITY   (Taiwan)

Author keywords

Drug analysis; Drug impurity profiling; Drug purity; Pharmaceutical impurities

Indexed keywords

EID: 33645774705     PISSN: 09491775     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00769-006-0095-y     Document Type: Article

References (35)

1. Barber HJ (1978) Historical aspects of chemotherapy. May and Baker Ltd., Dagenham, UK
2. De Quincey T (1972) Confessions of an English opium-eater. Dent TM and Sons Ltd., London
3. International Conference on Harmonisation, ICH (1997) Q3C Impurities: residual solvents, USA
4. International Conference on Harmonisation, ICH (2003) Q1A (R2) Stability testing of new drug substances and products, USA
5. International Conference on Harmonisation, ICH (2000) Analytical procedures and methods validation, USA
6. International Conference on Harmonisation, ICH (1995) Quality of biotechnological products: stability testing of biotechnological biological products, USA
7. International Conference on Harmonisation, ICH Specifications (1999) Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances, USA
8. Food and Drug Administration, FDA (1998) Guidance for industry: stability testing of drug substances and drug administration. Rockville, MD
9. World Health Organization, WHO (1996) Guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms in WHO expert committee on specifications for pharmaceutical preparations. Technical Report Series 863, Geneva
10. Committee for Proprietary Medicinal Product, CPMP (1988) Note for guidance on stability testing of existing active substances and related finished products. EMEA, London, UK
11. International Conference on Harmonisation, ICH (1995) Q2A, Validation of analytical procedures (definitions and terminology), USA
12. International Conference on Harmonisation, ICH (1996) Q2B, Validation of analytical procedures: methodology, USA
13. Ahuja S (1998) Impurities evaluation of pharmaceutical. Marcel Dekker, New York
14. Gorog S (2000) Identification and determination of impurities in drugs. Elsevier Science Publishing Company, Amsterdam
15. Berridge JC (1995) J Pharm Biomed Anal 14:7-12
16. Krstulovic AM, Lee CR (1997) J Chromatogr B 689:137-153
17. Rao RN, Nagaraju V (2003) J Pharm Biomed Anal 33:335-377
18. Rompay JV (1986) J Pharm Biomed Anal 4:725-732
19. Gorog S (2003) Anal Bioanal Chem 377:852-862
20. Ermer J (1998) J Pharm Biomed Anal 18:707-714
21. Vuletic M, Cindric M, Koruznjak JD (2005) J Pharm Biomed Anal 37:715-721
22. Alsante KM, Hatajik TD, Lohr LL, Sharp TR (2001) Am Pharm Rev 4:70-78
23. Corcoran O, Nicholson JK, Lenz EM, Abou-Shakara F, Castro-Perez J, Sage AB, Wilson ID (2000) Rapid Commun Mass Spectrom 14:2377-2384
24. Rahman N, Khan NA, Azmi SNH (2004) Anal Sci 20:1231-1236
25. Rahman N, Ahmad Y, Azmi SNH (2005) AAPS PharmSci Technol 6:543-551
26. Rahman N, Rahman H, Azmi SNH (2005) Chem Pharm Bull 53:942-948
27. Rahman N, Azmi SNH (2005) Acta Biochim Pol 52:915-922
28. Khan MA, Sinha S, Vartak SV, Bhartiya A, Kumar S (2005) J Pharm Biomed Anal 39:928-943
29. Khan MA, Kumar S, Jayachandran J, Vartak SV, Bhartiya A, Sinha S (2005) Chromatographia 61:599-607
30. Rao RN, Nagaraju V (2004) J Pharm Biomed Anal 36:729-735
31. Cannazza G, Di Stefano A, Mosciatti B, Braghiroli D, Baraldi M, Pinnen F, Sozio P, Benatti C, Parenti C (2005) J Pharm Biomed Anal 36:1079-1084
32. Liu J, Lou YJ (2004) J Pharm Biomed Anal 36:365-370
33. Altria KD (1993) J Chromatogr A 646:245-257
34. Hows MKP, Lacroix L, Heidbreder C, Organ AJ, Shah AJ (2004) J Neurosci Methods 138:123-132
35. Holt RM, Newman MJ, Pullen FS, Richards DS, Swanson AG (1997) J Mass Spectrom 32:64-70